Healthcare Industry News: InterMune
News Release - October 16, 2006
Zogenix Appoints J.D. Haldeman Vice President, Commercial Strategy & Corporate Communications
SAN DIEGO--(HSMN NewsFeed)--Zogenix, Inc., a privately held CNS-focused specialty pharmaceutical company, announced today that J.D. Haldeman has been appointed vice president, Commercial Strategy and Corporate Communications, and an officer of the company.Ms. Haldeman brings a breadth of experience across multiple commercial roles, including strategic product planning, new product launches, brand management, sales, business development, and corporate communications. Ms. Haldeman has more than 17 years of commercial pharmaceutical experience. Her last nine years have been focused on senior leadership roles in development-stage and early commercial-stage companies in the pharmaceutical, diagnostic, and drug delivery arenas.
Before joining Zogenix, Ms. Haldeman was vice president, Marketing at InterMune, where she managed the full scope of marketing activities for their hepatology, pulmonology, and oncology businesses. Previously, Ms. Haldeman spent nine years at Parke-Davis (now Pfizer) where she co-led the launch of Neurontin®, one of the industry's most successful CNS products, and rose to the level of senior director, Cardiovascular Disease Team.
"J.D. brings a wealth of knowledge and commercial experience to our management team," said Roger Hawley, Zogenix's chief executive officer. "She will be immediately focused on our pre-launch commercial activities, including branding, final packaging, marketing strategy and launch planning. J.D. will also play a key role as we build our commercial organization in 2008. She has a passion for introducing new treatment options, like our Intraject® technology, to patients and healthcare professionals, and she will be a driving force as we move quickly toward the launch of our first product, sumatriptan Intraject."
About Zogenix, Inc.
Zogenix, Inc., with offices in Hayward and San Diego, CA, is a private, specialty pharmaceutical company focused on the development and commercialization of medicines to treat CNS disorders and pain. The company's initial focus is the completion of the late-stage development and commercialization of sumatriptan Intraject® -- a needle-free, single-use, disposable, and easy-to-use subcutaneous delivery system that will compete in the $2.5 billion triptan segment of the migraine market. Additional information on the company can be found at www.zogenix.com.
Intraject is a registered trademark of Zogenix, Inc.
Neurontin is a registered trademark of Pfizer, Inc.
Source: Zogenix
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
